Abu Dhabi Set to Host AIM Congress 2025, Featuring Over 25,000 Participants From 180 Countries
4.9.2024 16:14:00 CEST | Business Wire | Press release
AIM Congress, the world’s premier investment platform, is set to convene in Abu Dhabi from April 7-9, 2025, under the theme “Mapping the Future of Global Investment: The New Wave of a Globalized Investment Landscape- Towards a New Balanced World Structure”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904975010/en/
HE Dr. Thani Al Zeyoudi - UAE Minister of State for Foreign Trade and President of AIM Congress (Photo: AETOSWire)
AIM 2025 will bring together industry leaders, government officials, policymakers, senior regional and international investors, as well as prominent international companies and organizations from various sectors. It will explore the latest trends, developments and opportunities shaping the global investment landscape, focusing on addressing current and future challenges and mobilizing efforts to forge innovative solutions, with the goal of fostering a prosperous and sustainable global economy.
HE Dr.Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade and President of AIM Congress, emphasized the significance of this gathering, stating, “AIM Congress 2025 is an opportunity to reaffirm the UAE’s unwavering commitment to leading global efforts in addressing the pressing economic challenges of our time. As the world navigates profound economic shifts, AIM will provide a crucial platform for the international community to come together, devise innovative investment strategies, and build a framework that ensures sustainable and inclusive growth for all.”
To accommodate the increased number of events, activities and exhibitors, the exhibition area will be doubled to over 30,000 m2. The event will host more than 25,000 distinguished participants from 180 countries, with over 1,000 speakers expected to engage in more than 350 panel discussions. To register your interest, kindly visit: www.aimcongress.com.
AIM Congress 2025 will feature events, forums, dialogue sessions, workshops, high-level meetings, the AIM Investment Awards and Exhibition, a startups competition, and showcases of country-specific investment opportunities. With two additional portfolios, AIM 2025 will tackle eight key portfolios, including Foreign Direct Investment (FDI), Global Trade, Startups & Unicorns, Future Cities, Future Finance, Global Manufacturing, Digital Economy, and Entrepreneurs.
Dawood Al Shezawi, Chairman of the Organizing Committee of AIM Congress, emphasized the event's ongoing success and increasing participation, noting that the Organising Committee is dedicated to organizing a bigger and more impactful edition to further shape a more prosperous and inclusive global economy.
For more information, click here
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904975010/en/
Contacts
Shereen al Musalami
Shereen al Musalami
shereen.almusallami@aimcongress.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom